King J, Waxman J, Stauss H
Department of Immunology, Imperial College London, London W12 0NN, UK.
QJM. 2008 Sep;101(9):675-83. doi: 10.1093/qjmed/hcn050. Epub 2008 May 13.
The clinical goal of tumour immunotherapy is to provide either active or passive immunity against malignancies by harnessing the immune system to target tumours. Although vaccination is an effective strategy to prevent infectious disease, it is less effective in the therapeutic setting for cancer treatment, which might be related to the low immunogenicity of tumour antigens and the reduced immunocompetence of cancer patients. Recent advances in technology have led to the development of passive immunotherapy approaches that utilize the unique specificity of antibodies and T cell receptors to target selected antigens on tumour cells. These approaches are likely to benefit patients and alter the way that clinicians treat malignant disease. In this article we review recent advances in the immunotherapy of cancer, focusing on new strategies to enhance the efficacy of passive immunotherapy with monoclonal antibodies and antigen-specific T cells.
肿瘤免疫疗法的临床目标是通过利用免疫系统靶向肿瘤，来提供针对恶性肿瘤的主动或被动免疫。尽管疫苗接种是预防传染病的有效策略，但在癌症治疗的治疗环境中效果较差，这可能与肿瘤抗原的低免疫原性和癌症患者免疫能力降低有关。技术的最新进展导致了被动免疫疗法的发展，该疗法利用抗体和T细胞受体的独特特异性来靶向肿瘤细胞上的选定抗原。这些方法可能会使患者受益，并改变临床医生治疗恶性疾病的方式。在本文中，我们回顾了癌症免疫疗法的最新进展，重点关注提高单克隆抗体和抗原特异性T细胞被动免疫疗法疗效的新策略。
